The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 767-772

  Badolo, Lassina ^a   Bundgaard, Christoffer ^a   Garmer, Mats ^a   Jensen, Bente ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Drug drug interactions; Hepatocytes; Organic anion transporting polypeptides (Oatps); Pharmacokinetics; Rat; Transporter

Indexed keywords

CYTOCHROME P450; DIPHENHYDRAMINE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE; PRAVASTATIN; REPAGLINIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84879801796     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.04.030     Document Type: Article

References (17)

1. Badolo, L., Rasmussen, L.M., Hansen, H.R., Sveigaard, C., 2010. Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension. Eur. J. Pharm. Sci. 40, 282-288.
2. Bow, D.A., Perry, J.L., Miller, D.S., Pritchard, J.B., Brouwer, K.L., 2008. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab. Dispos. 36, 198-202.
3. Cui, Y., Konig, J., Nies, A.T., Pfannschmidt, M., Hergt, M., Franke, W.W., Alt, W., Moll, R., Keppler, D., 2003. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83, 527-538. (Pubitemid 36457707)
4. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., Zhang, L., 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236.
5. Hagenbuch, B., Gui, C., 2008. Xenobiotic transporters of the human organic anion transporting polypeptides (OATPs) family. Xenobiotica 38, 778-801.
6. Hewitt, N.J., Lechon, M.J., Houston, J.B., Hallifax, D., Brown, H.S., Maurel, P., Kenna, J.G., Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A.P., LeCluyse, E., Groothuis, G.M., Hengstler, J.G., 2007. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159-234.
7. Jacobsen, J.K., Jensen, B., Skonberg, C., Hansen, S.H., Badolo, L., 2011. Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes. Eur. J. Pharm. Sci. 44, 427-436.
8. Jorgensen, L., Van, B.J., Lund, S., Schousboe, A., Badolo, L., 2007. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur. J. Pharm. Sci. 30, 181-189. (Pubitemid 46149281)
9. Kalliokoski, A., Niemi, M., 2009. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705.
10. Kalliokoski, A., Neuvonen, M., Neuvonen, P.J., Niemi, M., 2008. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol. 48, 311-321. (Pubitemid 351257770)
11. Kalliokoski, A., Neuvonen, P.J., Niemi, M., 2010. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin. Pharmacol. Toxicol. 107, 775-781.
12. Kivisto, K.T., Niemi, M., 2007. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24, 239-247. (Pubitemid 46072183)
13. Lai, Y., Varma, M., Feng, B., Stephens, J.C., Kimoto, E., El-Kattan, A., Ichikawa, K., Kikkawa, H., Ono, C., Suzuki, A., Suzuki, M., Yamamoto, Y., Tremaine, L., 2012. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. Exp. Opin. Drug Metab. Toxicol. 8, 723-743.
14. Menochet, K., Kenworthy, K.E., Houston, J.B., Galetin, A., 2012. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J. Pharmacol. Exp. Ther. 341, 2-15.
15. Niemi, M., Backman, J.T., Kajosaari, L.I., Leathart, J.B., Neuvonen, M., Daly, A.K., Eichelbaum, M., Kivisto, K.T., Neuvonen, P.J., 2005. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468-478. (Pubitemid 40824960)
16. Scheen, A.J., 2007. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin. Pharmacokinet. 46, 93-108. (Pubitemid 46193056)
17. Yoshida, K., Maeda, K., Sugiyama, Y., 2012. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin. Pharmacol. Ther. 91, 1053-1064.